Every intervention Outliyr has scored for healthy aging, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for healthy aging; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
68 of 111 evaluated interventions score 3.0+ out of 10 for healthy aging · 18 comparisons
Xie 2026 reports 9 RCTs; 496 participants; improved handgrip strength, gait speed, SPPB, and sit-to-stand with low-to-very-low certainty. Thavonlun 2026 points in the same direction, but route, dose, baseline status, and outcome…
Soh 2024 anchors the most relevant signal. Glycine fits geriatric because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because many…
Whole-Body Vibration may help preserve functional mobility in this population by stimulating muscle spindles and enhancing neuromuscular activation, mechanisms that support balance and gait. Evidence from randomized trials shows modest improvements in…
Chilibeck 2017 reports Older adults; +1.37 kg lean mass; leg press SMD 0.24. Van 2009 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate…
Lixandrao et al. 2018 supports the core mechanism. Centner 2019 found BFR increased strength and muscle mass in older adults, especially when heavy lifting was less practical. The score stays bounded because…
Kodama 2009 supports the strongest part of the claim. The existing rationale points to this narrower claim: Moderate aerobic training is highly relevant for older adults because it improves walking capacity, blood…
Kemmler-group RCTs and the Yang 2022 sarcopenic-obesity meta-analysis support lean-mass and physical-function gains in older adults, while Bloeckl 2022 supports feasibility and safety in frail older people under supervision. That makes Full-Body…
Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits geriatric when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is…
Filip 2007 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Cleanest responder profile is adults 50+ with lower endogenous AKG and higher frailty risk. this verified…
Schwarz 2022 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Older adults are the clearest target population across this verified source and this verified source. That…
The Norwegian 4x4 regimen involves four minutes of near-maximal effort followed by three minutes of active recovery, repeated four times. Evidence from umbrella reviews and meta-analyses places HIIT at a Tier 2…
Older adults have higher protein needs and greater sarcopenia relevance. The strongest support comes from Shimomura Y. et al. 2006, but the practical rating stays bounded by study size, replication, and how…
Menon 2025 anchors the most relevant signal. Lion's Mane fits geriatric when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or gut-immune signaling over weeks. The score stays bounded…
Karavidas et al. 2007 gives the strongest anchor. Age-related HRV decline makes training especially relevant; positive small trials in older adults. The score stays bounded because HRV Biofeedback evidence for geriatric can…
Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. Laurindo 2025 points in the same direction, but route, dose,…
Older adults are the primary target population. Crook 1991 and Cenacchi 1993 support the core signal, while modern S-PS findings are smaller and less consistent. The score stays bounded because Phosphatidylserine evidence…
Metformin may improve glycemic control in older adults, but renal decline, frailty, reduced appetite, vitamin B12 depletion, and drug interactions are common concerns. Guidelines from the ADA and NICE stress individualized dosing…
The evidence points to a plausible use case without proving a universal response. Kozina et al. 2007 is the best anchor here because it reports old-rat antioxidant-system evidence for pineal geroprotective peptides.…
Much of the KIHD cohort benefit accrued in middle-aged and older men followed into older age, and the cardiovascular, hypertension, and dementia associations from Laukkanen 2017 are exactly the outcomes that matter…
Strong target population. Koenig 2018 supports postmenopausal bone outcomes and Zdzieblik 2015 supports older men in resistance training. That makes Collagen Peptides more defensible when geriatric is a real bottleneck and less…
Age-related decline in endogenous GHK and cellular repair signaling supports the preserved geriatric score, especially in older skin. Pickart 2015 and He 2024 support age-repair and fibrosis mechanisms, but clinical geriatric outcomes…
Zhang et al. 2025 is the best anchor here because it reports 25 randomized trials, 1486 participants and improved fasting glucose, HbA1c, total cholesterol, systolic blood pressure, and diastolic blood pressure, with…
Glutathione synthesis is documented to fall with age in Sekhar 2011, and correcting it produced functional gains: Kumar 2023 reported significant improvements in gait speed, grip strength, and the chair-rise test in…
The existing rationale points to this narrower claim: Age-related testosterone decline is the clearest responder profile. the cited study, the cited study, and Leitão 2021 all fit older or aging-male. That does…
Tesamorelin targets an age-sensitive GH/IGF-1 axis and may improve VAT, cognition, and muscle quality in select older adults, but the geriatric case is conditional. Adrian 2019 supports exploratory muscle-quality changes in HIV…
Resnick 2017 reports T Trials cognition substudy; null for memory and executive-function benefit. Snyder 2016 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether TRT (Testosterone…
Older-adult cognition, telomere work, wound care, and radiation-injury data make geriatric one of the more relevant off-label slugs. Hadanny 2020 supports cognitive gains in adults age 64 and older after hard-chamber protocols.…
Vitamin C deficiency is more common in the elderly because of lower dietary intake, reduced appetite, and higher prevalence of smoking and chronic illness, and the consequences (poor wound healing, fatigue, fragile…
Pandit 2016 anchors the most relevant signal. Shilajit fits geriatric when purified resin is matched to hormones, sperm parameters, strength fatigue, bone markers, or energy tracking. The score stays bounded because most…
Two things that strongly predict independence in older adults, aerobic capacity and the ability to carry load, are exactly what a scalable loaded-walking protocol trains, and walking volume itself tracks lower mortality…
The signal is conditional. Older adults may benefit metabolically, but polypharmacy raises the practical risk. Guo 2012 supports human CYP inhibition concerns relevant to statins, anticoagulants, transplant drugs, and antidepressants. That makes…
Aging is exactly where the associations cluster. Blood ergothioneine declines after age 60 per Cheah 2016, and low levels track with frailty in Kondoh 2022 and with cognitive decline and mortality across…
Older adults are the best-studied human group. Liu 2022 studied adults aged 65-90 and found muscle-endurance plus biomarker signals. That makes Urolithin A more defensible when geriatric is a real bottleneck and…
Zhang 2024 anchors the most relevant signal. NMN fits geriatric when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more…
Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain…
Borra 2025 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Older adults have higher dehydration risk due to reduced thirst and medication burden. Electrolyte use should…
Anxiety and sleep applications are relevant, and safety is clean, but older adults taking antihypertensives or sedatives should be more cautious. That makes L-Theanine more defensible when geriatric is a real bottleneck…
Older adults are the most clinically relevant population because Semax evidence concentrates around stroke and neurorecovery, including Gusev et al. 2018, but Western geriatric guidance is absent. That makes Semax more defensible…
The evidence points to a plausible use case without proving a universal response. Fatima et al. 2024 is the best anchor here because it reports five randomized trials, 254 participants and reduced…
Abuknesha et al. 2025 is the best anchor here because it reports 34 randomized trials, 114,326 participants and atrial fibrillation risk concentrated in high-cardiovascular-risk participants receiving high-dose EPA/DHA. Raine et al. 2024…
Geriatric relevance is stronger because endogenous MOTS-c changes with age and Reynolds 2021 tested late-life mouse physical-capacity effects. Human geriatric intervention trials remain absent. That makes MOTS-c more defensible when geriatric is…
Older adults with vascular or post-stroke cognitive impairment are the only population noopept has actually been tested in, so the geriatric relevance is direct rather than inferred. The post-stroke study enrolled 60…
Conze 2019 anchors the strongest signal. The existing rationale points to this narrower claim: Older adults have larger NAD+ decline, but this verified source did not support NR or NMN for preserving…
Older adults can gain real VO2max from interval work when intensity is scaled and medically screened, and even high-intensity intervals are well tolerated under supervision in older clinical populations per Rognmo 2012.…
Semaglutide can help older adults with high obesity or diabetes risk, but sarcopenia risk makes casual use harder to justify. Perkovic 2024 supports kidney benefit in type 2 diabetes plus CKD, a…
The one pivotal muscle trial in a non-cancer population was run specifically in healthy older men and postmenopausal women, so the aging-muscle relevance is direct rather than inferred (Dalton et al. 2011).…
Older adults are the most plausible healthy-aging group, but benefits remain surrogate-based and risks rise with comorbidity and polypharmacy.
Plausible for older adults given the cardiometabolic effects and complete protein, but dedicated trials in geriatric populations are sparse; sourcing caution matters more in vulnerable groups.
Older adults are over-represented in the indications where Tβ4 has the most data (neurotrophic keratopathy, dry eye, chronic wounds, cardiac repair), and the safety record in older trial subjects is clean. No…
Older adults need caution because sarcopenia, bone density, cardiovascular disease, medication burden, and APOE status all matter. Keto can help supervised T2D and epilepsy cases, but Mediterranean-style patterns usually have stronger preventive-care…
Older adults with obesity, diabetes, OSA, or HFpEF may benefit. Frailty, sarcopenia, dehydration, constipation, polypharmacy, gallbladder risk, and bone risk are major limiters. Cap scoring unless protein, resistance training, medication review, and…
The cardiac and brain-fuel mechanisms are most interesting in older adults, and the heart-failure work (Nielsen 2019) involves an older population, but this remains clinical and investigational rather than a general geriatric…
Geriatric use is context-dependent. Older adults with impaired glucose tolerance or postmenopausal women with cerebrovascular/cognitive goals are the most plausible responders, supported indirectly by the impaired-glucose-tolerance pilot literature and directly by Thaung…
An exercise mimetic could be useful for sedentary older adults if safe, but that is exactly the population where untested safety matters most. Bonanni et al. 2025 adds human myoblast pilot context,…
Healing acceleration is particularly valuable in aging populations. Older adults also face higher cancer, vascular, anticoagulation, and polypharmacy risk, so the caution bar is higher.
Older-adult relevance comes through IPF, D plus Q, BP, and cohort signals such as Hertog 1993 and Nambiar 2023. Drug interaction concerns are amplified by polypharmacy and renal aging. Senolytic class pilots…
The clean safety profile and broad nutrient load make chlorella a reasonable food-based addition for older adults with borderline lipids, but no aging-population outcome trials specifically support it, so the case is…
Babiloni-Lopez 2024 gave 93 older women microfiltered seawater alongside resistance training over 32 weeks with no adverse events and blood pressure that fell in training arms; the benefit tracked the exercise, not…
The osteoarthritis and inflammation use cases are especially relevant to older adults, though the liver-injury caution matters more with polypharmacy.
Older adults with obesity may benefit metabolically, but sarcopenia, frailty, dehydration, falls, polypharmacy, and appetite suppression make unsupervised use risky. No geriatric-specific retatrutide outcomes establish net benefit.
Widely used in older adults for arthritis, but NSAID cardiovascular, kidney, blood-pressure, and gastrointestinal risks are amplified with age. The geriatric score reflects utility plus elevated monitoring burden.
Older adults may benefit indirectly from immune and gut support, but geriatric-specific evidence is limited. Duff 2014 is not enough to support a broad aging claim.
Gut and inflammatory uses are relevant to older adults, but the sodium load matters more with kidney or blood-pressure issues.
Modafinil geriatric use requires lower-dose caution and closer monitoring. DailyMed 2026 recommends considering lower doses and monitoring in geriatric patients. Diagnosed sleepiness can justify use, but polypharmacy, cardiovascular disease, and slower clearance…
Older adults are the population where pine pollen's preclinical story is most coherent. Mao 2012 improved memory and lowered inflammatory cytokines in D-galactose-aged mice, and Polak 2025 limited bone atrophy in orchidectomized…
The sarcopenia work was done in aged mice, so the aging-population relevance is real but remains preclinical (Dantas et al. 2022).
No randomized C15:0 supplementation trial has tested adults over 65 against frailty, sarcopenia, cognitive decline, falls, or survival. Ciesielski 2024 (Ciesielski 2024) keeps the biology open rather than settled. Given unresolved cognitive-safety…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 20 of 68 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Essential Amino Acids | Not priced yet | ||
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Creatine Monohydrate | Not priced yet | ||
| Blood-Flow Restriction Training | Not priced yet | ||
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Full-Body EMS | Not priced yet | ||
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Grass-Fed Whey Protein | $40–$80 | 20-40 g protein | Over the counter |
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Astaxanthin | Not priced yet | ||
| Phosphatidylserine | $20–$50 | 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Epitalon | $95–$1,100 | 5-10 mg/day subcutaneous | Grey market |
| Traditional Sauna (Finnish Dry-Heat) | $50 | 15 to 20 minutes at 80 to 100 C | Over the counter |
| Collagen Peptides | $8–$40 | 2.5-10 g hydrolyzed collagen peptides | Over the counter |
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Saffron | Not priced yet | ||
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Vitamin C (Ascorbic Acid) | Not priced yet | ||
| Shilajit | $25–$50 | 500 mg purified shilajit | Over the counter |
| Rucking (Weighted Walking) | Not priced yet | ||
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| Ergothioneine | Not priced yet | ||
| Urolithin A | $50–$100 | 500 mg/day | Over the counter |
| NMN (Nicotinamide Mononucleotide) | $40–$100 | 500 mg/day oral | Over the counter |
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| Electrolytes | Not priced yet | ||
| L-Theanine | $3–$8 | 200 mg L-theanine + 100 mg caffeine | Over the counter |
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Ashwagandha | $15–$30 | 300 mg KSM-66 with breakfast and 300 mg with dinner | Over the counter |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| MOTS-c | $100–$200 | 5-10 mg SC | Research use only |
| Noopept (Omberacetam) | $5–$27 | 20 mg | Grey market |
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Ostarine (MK-2866 / enobosarm) | Not priced yet | ||
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Exogenous Ketones | $38–$300 | Ester 10 to 25 g BHB | Over the counter |
| Resveratrol | Not priced yet | ||
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Chlorella | $10–$50 | 5-10 g/day | Over the counter |
| Glutathione (GSH) | $20–$45 | 1,000 mg/day | Over the counter |
| Quinton Marine Plasma (Seawater Minerals) | Not priced yet | ||
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| Celebrex (Celecoxib) | Not priced yet | ||
| Colostrum | $60–$80 | 20 g/day powder, split AM/PM if tolerated | Over the counter |
| Sodium Butyrate | Not priced yet | ||
| Modafinil | $18–$35 | 200 mg oral tablet | Prescription |
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
| BAM15 | Not priced yet | ||
| C15 (Pentadecanoic Acid) | $40–$50 | 200 mg/day | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
This page ranks by the live Body Composition subrating, fat loss and body composition, not the overall BioHarmony score. Tesamorelin leads at 7.5–8.0/10, and it also carries the…
Semax scores 7.1/10 against noopept's 6.2/10 and wins five of the eight use cases both reports score. Noopept is oral, cheaper at $5 to $27 a month, and…
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Tesamorelin, unless price is the only thing deciding. It is FDA-approved for visceral fat with Phase 3 trials behind it, while CJC-1295 is a gray-market research peptide whose…
These two get sold as the same thing, a scoop for gut and skin, and they share almost no mechanism. Colostrum is a gut and immune product: gut…
Epitalon, if sleep is the question. It scores sleep quality 6.5–7.0/10 against pinealon's 1.5–2.0/10, because it acts on the pineal gland and melatonin output while pinealon is a…
No, and the reason is mechanical. A drink raises blood ketones in an hour. It does not lower insulin, deplete glycogen or shift fuel use. The diet scores…
Start on sermorelin. Ipamorelin scores higher overall, yet sermorelin wins thirteen of the sixteen shared use cases and it is the one an anti-aging clinic actually prescribes. Ipamorelin…
Spermidine scores 7.5–8.0/10 and urolithin A 6.5–7.0/10, and they clean up different messes. Spermidine drives broad autophagy: autophagy 8.0/10, cardiovascular 7.8/10, longevity 7.5/10. Urolithin A drives selective mitophagy…
Thymulin scores 6.5–7.0/10, thymalin 5.5–6.0/10, and they are not interchangeable. Thymulin is a defined zinc-dependent peptide with receptor-level science, stronger inflammation data and a much cheaper course. Thymalin…
Semax scores 7.0–7.5/10 and cerebrolysin 6.0–6.5/10. Semax wins cognition, neuroplasticity and nerve regeneration, costs an estimated $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.0–7.5/10 against dihexa's 4.0–4.5/10, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
Essential Amino Acids, at 8.5–9.0 out of 10 for healthy aging. Xie 2026 reports 9 RCTs; 496 participants; improved handgrip strength, gait speed, SPPB, and sit-to-stand with low-to-very-low certainty.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 8.5–9.0 out of 10 for healthy aging.
C15 (Pentadecanoic Acid) scores 3.0–3.5 out of 10 for healthy aging but only 3.0–3.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
68 of the 111 interventions evaluated for healthy aging score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
